The genomes of cancer cells usually contain a large number of
aberrations (point mutations, copy number alterations [CNAs],
chromosome translocations and epigenetic changes), which
include causative genetic alterations (drivers) and a far greater
number of genetic events (passengers) that do not influence cancer
progression [1]. Identification of cancer drivers will advance our
understanding of cancer biology and ultimately enable personalized
cancer therapies. However, distinguishing drivers from
passengers remains difficult because of the number and variability
of genomic alterations in cancer cells.